ELEV
Elevation Oncology
ELEV
ELEV
Delisted
ELEV was delisted on the 22nd of July, 2025.
25 hedge funds and large institutions have $16.1M invested in Elevation Oncology in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
25% less capital invested
Capital invested by funds: $21.5M → $16.1M (-$5.38M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Holders
25
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$72.4K | |
| 2 | +$34.2K | |
| 3 | +$34K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.82K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$5 |
Top Sellers
| 1 | -$1.22M | |
| 2 | -$250K | |
| 3 | -$76.6K | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$35.2K |
| 5 |
VF
Virtu Financial
New York
|
-$31K |